OptiNose presents fluticasone study results
The results showed that administering fluticasone with OptiNose’s device is effective in the treatment of refractory CRS, with significant and clinically relevant improvements compared with placebo in both
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.